ALX Oncology Holdings Inc. (ALXO): Price and Financial Metrics

ALX Oncology Holdings Inc. (ALXO): $12.61

0.42 (-3.22%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

D

ALXO Price/Volume Stats

Current price $12.61 52-week high $17.42
Prev. close $13.03 52-week low $3.94
Day low $12.56 Volume 37,439
Day high $13.10 Avg. volume 389,646
50-day MA $13.58 Dividend yield N/A
200-day MA $9.71 Market Cap 632.39M

ALXO Stock Price Chart Interactive Chart >


ALX Oncology Holdings Inc. (ALXO) Company Bio


ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia on April 1, 2020 and is headquartered in Burlingame, CA.


ALXO Latest News Stream


Event/Time News Detail
Loading, please wait...

ALXO Latest Social Stream


Loading social stream, please wait...

View Full ALXO Social Stream

Latest ALXO News From Around the Web

Below are the latest news stories about ALX ONCOLOGY HOLDINGS INC that investors may wish to consider to help them evaluate ALXO as an investment opportunity.

7 Small-Cap Stocks That Wall Street Loves for Good Reason 

The market rally is showing signs of broadening to include small-cap stocks, here are seven that analysts are upgrading

Chris Markoch on InvestorPlace | December 22, 2023

ALX Oncology Holdings Inc (ALXO) Reports Q3 2023 Financial Results and Corporate Developments

Positive Clinical Trial Results and Public Offering Highlight the Quarter

Yahoo | November 13, 2023

ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update. Third Quarter 2023 Highlights and Recent Developments Reported positive interim Phase 2 ASPEN-06 clinical trial results for evorpacept for the treatme

Yahoo | November 13, 2023

ALX Oncology Announces November Investor Conference Participation

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that management will participate in three upcoming investor conferences in November. 2023 UBS BioPharma ConferenceFormat: Fireside chat with analyst, Dr. Colin BristowDate: Wednesday, November 8thTime: 1:30 PM ESTLocation: Miami Beach, FLWebcast link: Availa

Yahoo | November 1, 2023

ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the closing of its previously announced underwritten public offering of common stock and pre-funded warrants. ALX Oncology sold 8,663,793 shares of common stock, which included 1,293,103 shares of common stock pursuant to the full exercise of the u

Yahoo | October 10, 2023

Read More 'ALXO' Stories Here

ALXO Price Returns

1-mo 11.59%
3-mo -9.74%
6-mo 63.77%
1-year 162.71%
3-year -79.24%
5-year N/A
YTD -15.31%
2023 32.12%
2022 -47.56%
2021 -75.07%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!